Can you take Daclizumab with Panamax?

The acetaminophen in Panamax has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

The acetaminophen in Panamax has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Daclizumab has a major potential interaction with Depression.

Depression-related events, including suicidal ideation or suicide attempt, have been reported with the use of daclizumab. If severe depression and/or suicidal ideation is present, consider discontinuation of therapy. Caution is recommended when using this agent in patients with previous depressive disorders.

Daclizumab has a moderate potential interaction with Eczema.

Serious skin reaction, including photosensitivity reactions, have occurred in patients treated with daclizumab. It is recommended to use daclizumab with caution in patients with a history of skin conditions, including eczema or psoriasis, as the use of this agent may exacerbate those conditions. If a patient develops a serious diffuse or inflammatory rash, it is recommended to evaluate the patient before the next dose and to discontinue treatment as appropriate.

Daclizumab has a major potential interaction with Infection.

Infections of the upper respiratory tract, urinary tract, and viral infections, sometimes serious, have been reported with the use of daclizumab. It is recommended to avoid daclizumab in patients with a severe active infection. Monitor for signs and symptoms of an infection and consider withholding treatment until the infection resolves.

Daclizumab has a major potential interaction with Liver Disease.

Daclizumab use can cause life-threatening severe liver injury, including liver failure and autoimmune hepatitis. The use of daclizumab is contraindicated in patients with a history of autoimmune hepatitis or other autoimmune condition involving the liver, and in patients with preexisting liver disease of hepatic impairment, including ALT or AST at least two times the upper limit of normal. Prior to starting therapy with daclizumab, it is recommended to obtain serum transaminases (ALT and AST) and total bilirubin levels in all patients. Continue to monitor levels of transaminase levels and total bilirubin monthly, before each next dose, and follow transaminase levels and total bilirubin monthly for 6 months after the last dose of daclizumab. Treatment modifications are recommended based on serum transaminase and total bilirubin values. If patients develop clinical signs or symptoms suggestive of hepatic dysfunction, immediately discontinue treatment and promptly measure serum transaminases and total bilirubin. Discontinue treatment if autoimmune hepatitis is suspected.

The acetaminophen in Panamax has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The acetaminophen in Panamax has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The acetaminophen in Panamax has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

Daclizumab has a moderate potential interaction with Psoriasis.

Serious skin reaction, including photosensitivity reactions, have occurred in patients treated with daclizumab. It is recommended to use daclizumab with caution in patients with a history of skin conditions, including eczema or psoriasis, as the use of this agent may exacerbate those conditions. If a patient develops a serious diffuse or inflammatory rash, it is recommended to evaluate the patient before the next dose and to discontinue treatment as appropriate.

Daclizumab has a major potential interaction with Tuberculosis, Active.

Tuberculosis has been reported with the use of daclizumab in countries where tuberculosis is endemic. Prior to initiating treatment, it is recommended to evaluate high-risk patients for tuberculosis infection. Patients testing positive for tuberculosis should be treated according to standard medical practice before initiating treatment with daclizumab.

Daclizumab has a major potential interaction with Tuberculosis, Latent.

Tuberculosis has been reported with the use of daclizumab in countries where tuberculosis is endemic. Prior to initiating treatment, it is recommended to evaluate high-risk patients for tuberculosis infection. Patients testing positive for tuberculosis should be treated according to standard medical practice before initiating treatment with daclizumab.